Ann Marie Swart.

Outcome Measures The principal outcomes of interest were progression-free survival and overall survival. Various other outcomes included biologic progression-free interval, response to therapy, toxicity, and quality of life. Progression-free of charge survival was calculated from the date of randomization to the date of the initial indication of disease progression or death, whichever occurred first; the data for individuals who were alive without disease progression were censored by the date of their last assessment.Patients who were under 55 years of age got either diabetes mellitus or a previous myocardial infarction in addition to the index event. Important exclusion criteria included a platelet count of less than 90,000 per cubic millimeter, a hemoglobin degree of less than 10 g per deciliter, or a creatinine clearance of significantly less than 30 ml each and every minute at screening; clinically significant gastrointestinal bleeding within 12 months before randomization; previous intracranial hemorrhage; and previous ischemic stroke or transient ischemic attack in patients who were taking both aspirin and a thienopyridine.